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ABSTRACT
Objectives: Cancer is a disease characterized by uncontrollable, irreversible, independent, autonomous, uncoordinated, relatively unlimited, and 
abnormal overgrowth of tissues. Breast cancer is the second most common type of cancer after lung cancer. The aim of the study is to carry out the 
docking studies, synthesis, and antitumor activities of benzothiazole derivatives containing oxadiazole groups or amino groups.
Methods: The docking studies of benzothiazole derivatives were done with known anticancer targets like estrogen receptor using Argus lab and 
AutoDock programs and compared with the standard drug tamoxifen. Based on the results obtained from the molecular modeling studies, the 
derivatives were selected for the synthesis. The synthesized compounds were characterized by melting point, thin layer chromatography, InfraRed,1H 
NMR,13CNMR, mass spectral data, and screened for their in-vitro anticancer activities.
Results: The docking scores obtained for benzothiazole derivatives (BT1, BT2, BT3, BT4) and std. tamoxifen from the preliminary docking program 
using Argus Lab were −9.68, −9.4, −9.59, −11.1988, −9.71 and using AutoDock program were −6.29, −5.25, −7.19, −7.48, −3.86, respectively. All the 
four derivatives were synthesized, characterized, and subjected to in vitro anticancer screening by MTT assay in breast cancer (MCF-7) cell lines. 
Compounds DBT1, DBT2, and DBT3 were the most active compounds against MCF-7 cell lines with inhibitory concentration 50% of 70.0, 64.0 and 
65.0, respectively.
Conclusion: All the four derivatives show good docking scores when compared to standard drug tamoxifen and can be concluded that all the 
synthesized benzothiazole ligands show good anticancer property.
Keywords: Benzothiazole, Oxadiazole, Estrogen receptor, Anticancer targets.
INTRODUCTION
Benzothiazole is a heterocyclic compound which possesses various 
biological activities. It is of great scientific interest nowadays. 
Benzothiazoles are fused membered rings which consist of thiazole 
ring fused with benzene ring. They are widely found in bio-organic 
and medicinal chemistry with application in drug discovery [1]. 
Benzothiazole moieties are part of compounds showing numerous 
biological activities such as antifungal [2], antiepileptic [3] 
anticancer [4], anti-inflammatory (COX-inhibitors) [5], antidiabetic [6], 
anticonvulsant [7], antimicrobial [8], diuretic [9], antitubercular [10], 
schictosomicidal [11], and anthelmintic [12] activities. Benzothiazole 
is used in research as a starting material for the synthesis of various 
bioactive structures. Its aromaticity makes it a relatively stable 
compound [13]. Drug design, sometimes referred to as rational drug 
design or more simply rational design, is the inventive process of 
finding new medications based on the knowledge of a biological target. 
The drug is most commonly an organic small molecule that activates or 
inhibits the function of a biomolecule such as a protein, which in turn 
results in a therapeutic benefit to the patient [14] Docking is a method 
which predicts the preferred orientation of one molecule to the second 
when bound to each other to form a stable complex. Breast cancer is 
a type of cancer originating from breast tissue, most commonly from 
the inner lining of milk ducts or the lobules that supply the ducts with 
milk.
METHODS
In silico molecular modeling
In silico drug, designing is a technique used for the design of new 
drug molecules, and the identification of drug targets using various 
bioinformatic tools with the help of computers. Analysis of Lipinski’s 
rule of five and determination of toxicity parameter was carried out.
Target identification and retrieval
Crystallographic structures of the target of interest were obtained from 
Protein Data Bank (PDB) and saved in standard three dimensional (3D) 
coordinate format. The selected target and its PDB ID are mentioned 
in Table 1.
Estrogen receptor (ER) [15]
Breast cancer, the most common malignancy in women, was already 
known to be associated with the steroid hormone estrogen. The 
discovery of the ER provided us not only with a powerful predictive 
and prognostic marker but also an efficient target for the treatment of 
hormone-dependent breast cancer with antiestrogens [16].
3D structures of inhibitors
The chemical structures of inhibitors were designed, and the structure 
was analyzed using Chemsketch. Molecular docking and visual 
inspection are carried out. The list of compounds undergone for 
docking studies was mentioned in Table 2.
Experimental part
Preparation of 4, 6-disubstituted-1,3-benzothiazol-2-amine 
derivatives
Substituted aniline and potassium thiocyanate were dissolved in 
ethanol containing 2 ml concentrated hydrochloric acid (HCL). To this, 
bromine in glacial acetic acid was added, and the reaction mixture was 
refluxed for 1 hr. Then, the mixture was poured into crushed ice. The 
precipitate obtained was strained well. It was then filtered, washed 
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with water and dried. The crude precipitate was recrystallized from 
rectified spirit [17]. The reaction is shown in Fig. 1.
Preparation of 2-(5-substituted-1, 3, 4-oxadiazole-2-yl)-1, 
3-benzothiazole
Step 1: Preparation of ethyl-2-benzothiazole carboxylate
Ethyl-2-benzothiazole carboxylate was synthesized by the following 
method. A mixture of o-aminothiophenol (0.1 mol) and diethyl oxalate 
(0.2 mol) was heated at mild reflux for 4 hrs, during which the temperature 
decreases from 147°C to 93°C. After cooling, the mixture was poured into 
a solution consisting of 50 ml of concentrated HCL, 150 ml of water and 
70 ml of ethanol. The oil got dissolved and a solid formed, upon stirring. 
The mixture was cooled. The product was filtered and washed with aq. 
Ethanol, then dried and finally recrystallized from pet ether.
Step 2: Preparation of 1, 3-benzothiazole-2-carboxyhydrazide
Into a clean, dry 100 mL round bottomed flask, the ethyl-2-benzothiazole 
carboxylate (1) (0.01 mol) was dissolved in ethanol (60 mL). The 
hydrazine hydrate (0.02 mol) (99%) was added drop by drop with 
constant stirring and the content were refluxed for 8 hrs, cooled to 
room temperature. The solid separated was filtered and washed with 
water, dried and finally crystallized from ethanol.
Step 3: Preparation of 2-(5-substituted-1, 3, 4-oxadiazole-2-yl)-1, 
3-Benzothiazole.
A mixture of 1, 3-benzothiazole-2-carboxyhydrazide (2) (0.01 mol), 
appropriate aromatic acid (0.02 mol) and phosphoryl chloride 
(10 mL) was refluxed on water bath for 6-8 hrs. After cooling to room 
temperature, it was poured into the crushed ice with stirring. The solid 
thus obtained was filtered, washed with water and crystallized from 
ethanol [18]. The reaction is shown in Fig. 2.
Spectral analysis
All the synthesized compounds were characterized by InfraRed (IR), 




3-(4,5–dimethyl thiazol–2–yl)–5–diphenyltetrazolium bromide (MTT), 
fetal bovine serum (FBS), phosphate buffered saline (PBS), Dulbecco’s 
Modified Eagle’s Medium (DMEM), and Trypsin were obtained from 
Sigma-Aldrich Co, St Louis, USA. Ethylenediaminetetraacetic acid 
(EDTA), glucose and antibiotics from Hi-Media Laboratories Ltd., 
Mumbai. Dimethyl sulfoxide (DMSO) and Propanol from E. Merck Ltd., 
Mumbai, India.
Cell lines and culture medium
MCF-7 cell line was procured from National Centre for Cell Sciences, 
Pune, India. Stock cells were cultured in DMEM, supplemented with 
10% inactivated FBS, penicillin (100 IU/ml), streptomycin (100 g/ml), 
and amphotericin B (5 g/ml) in an humidified atmosphere of 5% CO2 at 
37°C until confluent. The cells were dissociated with trypsin phosphate 
versene glucose solution (0.2% trypsin, 0.02% EDTA, 0.05% glucose 
in PBS). The stock cultures were grown in 25 cm2 culture flasks and 
all experiments were carried out in 96 microtitre plates (Tarsons India 
Pvt. Ltd., Kolkata, India).
Preparation of test solutions
For cytotoxicity studies, each test drug was weighed and mixed to 
obtain the desired concentration and dissolved in distilled DMSO and 
volume was made up with DMEM supplemented with 2% inactivated 
FBS to obtain a stock solution of 1 mg/ml concentration and sterilized 
by filtration. Serial two-fold dilutions were prepared from this for 
carrying out cytotoxic studies.
Determination of cell viability by MTT assay [19,20]
Procedure
The monolayer cell culture was trypsinized, and the cell count was 
adjusted to 1.0×105 cells/ml using DMEM containing 10% FBS. To 
Table 1: Selected target and its PDB ID
Target PDB ID
Estrogen receptor 3ERT
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each well of the 96 well microtiter plate, 0.1 ml of the diluted cell 
suspension (approximately 10,000 cells) was added. After 24 hrs, when 
a partial monolayer was formed, the supernatant was flicked off. The 
monolayer was washed once with the medium. 100 µl of different test 
concentrations of test drugs were added on to the partial monolayer 
in microtitre plates. The plates were then incubated at 37°C for 3 days 
in 5% CO2 atmosphere, and microscopic examination was carried out 
and observations were noted every 24 hrs interval. After 72 hrs, the 
drug solutions in the wells were discarded and 50 µl of MTT in PBS 
was added to each well. The plates were gently shaken and incubated 
for 3 hrs at 37°C in 5% CO2 atmosphere. The supernatant was removed 
and 100 µl of propanol was added, and the plates were gently shaken 
to solubilize the formed formazan. The absorbance was measured 
using a microplate reader at a wavelength of 540 nm. The percentage 
growth inhibition was calculated using the following formula and 
concentration of test drug needed to inhibit cell growth by 50% 
(cytotoxic concentration50) values is generated from the dose-response 
curves for each cell line.
Mean OD of 
individual test groupPercentage growth inhibition=100 100









Benzothiazole derivatives were subjected to molecular docking 
against ER. The resulting docking score helped to select the more 
potent derivatives for the synthesis. In silico studies were done using 
different softwares such as ArgusLab, AutoDock, ACD/Chemsketch, 
and molinspiration. ArgusLab serves as a primary docking tool. The 
prepared ligands were validated by docking operation using ArgusLab 
and AutoDock. The docking score of the ligands was compared with the 
reference standards. The docking scores obtained from the preliminary 
docking program using ArgusLab were listed in Table 3.
The docking scores were obtained from the analogs against ER 
receptors. All the compounds show good docking scores when 
compared to standard drug. Docking score of the compounds targeted 
ER was compared with the score of the drug Tamoxifen which is used 
as a potent drug for the treatment of breast cancer. Benzothiazole 
derivatives were docked with the crystallographic structures of the 
targets by AutoDock version 4.0 screening program as shown in Table 4. 
The analogs were examined for their binding energies and hydrogen 
bonding. The conformations with the highest binding energies and 
greater number of hydrogen bonds of all the ligands were taken in 
consideration for ranking the analogs. It is listed in Table 4.
All the analogs show higher docking scores when compared to standard 
drug. AutoDock shows lowest docking scores than ArgusLab but have 
more accuracy. All the ligands show good docking scores when compared 
to standard drug. The interactions were stronger (energetically lesser) 
for all the ligands which are used for docking simulation.
AutoDock screening program also helped to know about the hydrogen 
bonding interactions of all the derived compounds. It showed in Table 5.
Residues ARG 374, ARG 928, ARG 926, ASN 375, ARG 376, ARG 346, 
THR 206, TYR 385, HIS 386, THR 212, TRP 345, MET 421, and HIS 
524 were predicted as active site in the target proteins, ER. Number 
of hydrogen bonding will considerably increase the affinity of ligand-
target interaction. AutoDock results show that most of the benzothiazole 
derivatives show higher hydrogen bonding between the ligand-target 
interactions. Some of the derivatives showing oxadiazole moieties 
show more than two hydrogen bonds (commonly ARG 374, ASN 375 
Fig. 2: Reaction of 2-(5-substituted-1, 3, 4-oxadiazole-2-yl)-1, 
3-benzothiazole
Fig. 1: Reaction of 4,6-disubstituted -1,3-benzothiazol-2-amine 
derivatives
Table 3:Argus Lab docking scores for the designed 
Benzothiazole derivatives







Table 4: Ligand-target hydrogen bonding interactions







Table 5: AutoDock docking scores
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or ARG 376). This hydrogen bonding interactions help to increase the 
binding energy of ligand-protein interactions.
Some of the high docking scores ligand-target complexes with different 
hydrogen bonding interactions generated by AutoDock 4.0 program 
were shown in Fig. 4. in a separate file.
In silico analysis
Drug-likeness assessment
The derived analogs were evaluated for their drug-likeness. It was done 
by calculating the parameters like Lipinski rule of 5 and some of their 
extension parameters like number of rotatable bonds and cLog P. The 
drug-likeness assessments of the compounds were shown in Table 6.
This result showed that the value of all the derivatives relies within 
the optimal range. All the compounds had the molecular weight <500 
daltons and possessed number of hydrogen bond donors and hydrogen 
bond acceptors of all the analogs below 5 and 10, respectively. All the 
values of partition coefficient and number of rotatable bonds were 
coming under the limit of 5. All these data indicate that violations are 
unlikely and the compounds may form an orally active drug.
Toxicity parameters by means of ADMET predictor
ADMET predictor was a computer software system for predictive 
modeling of absorption, distribution, metabolism, elimination, and 
toxicity of chemical substances in the human body. The results for the 
toxicity parameters using ADMET predictor were shown in Table 7.
BBB: 0-very high penetration, 1-high penetration, 2-medium 
penetration, 3-low penetration, and 4-undefined. Absorption level: 
0-good absorption, 1-moderate absorption, 2-poor absorption, 
and 3-very low absorption. Solubility level: 0-very high solubility, 
1-high solubility, 2-medium solubility, 3-low solubility, and 4-undefined. 
Hepatotoxicity: 0-non-toxic, unlikely to cause dose-dependent liver 
injuries; 1-toxic, likely to cause dose-dependent liver injuries. CYP2D6 
Inhibition: 0-not a likely inhibitor; 1-potential inhibitor. Plasma protein 
binding (PPB) level: 0-binding is <90% (No markers flagged and 
AlogP98 < 4.0); 1-binding is = 90% (flagged at 90% or AlogP98 = 4.0); 
2-binding is = 95% (flagged at 95% or AlogP98 = 5.0).
Toxicity studies were carried out using ADMET SAR to determine their 
pharmacokinetic (ADMET) properties. A high degree of PPB implies 
high lipophilicity which makes the drug long-acting. All the compounds 
show high and medium penetration to penetrate blood–brain barrier. 
BT1and BT4 showed very good level of intestinal absorption after 
oral administration. BT2 has medium aqueous solubility, and all 
other compounds show low solubility. All the compounds show 
dose-dependent hepatotoxicity. CYP2D6 is the enzyme which 
metabolizes the 20% of the drug; all the compounds showed inhibition 
against CYP2D6. All the derivatives showed <90% binding to plasma 
proteins.
Synthesis
Benzothiazole analogs were screened by in silico molecular docking 
and analysis showed better activity against the selected anticancer 
targets. The selected derivatives were synthesized in two-step 
process by refluxing benzothiazolyl carboxyhydrazide with different 
aryl acids in phosphoryl chloride to give substituted benzothiazole 
derivatives. Prepared four compounds are DBT1, DBT2, DBT3, and 
DBT4.
Characterization of prepared compounds
DBT1
Molecular formula: C7H4Cl2N2S molecular Weight: 219.09
Melting point: 194-196°C percentage yield: 58.2%
Rf value: 0.64 (Pet.ether: Ethylacetate (1:1))
IR (KBr) 3367, 3455 (N-H str. Of 1º amine), 3071 (arom. –CH str), 
1457 (C=C str in aromatic hydrocarbons), 1292 (C-N str. Of amino grp), 
773 (C-Clstr).;1H NMR (DMSO, 400 MHz) δ5.563 (s, 1H), δ7.49 (s, 1H), 
δ7.42 (s, 1H)13C NMR (DMSO, 100MHz) δ160.33, 157.28, 149.09, 
148.79, 130.90, 129.94, 129.87, 129.57, 126.56, 121.80, 120.43; ESI 
MS (m/z relative abundance) 220 [(M+H)+, 28], 211 [(C7H3Cl2NS)+], 171 
[(C7H7Cl2)+,100].
DBT2
Molecular formula: C7H4F2N2S molecular Weight: 186.18
Melting point: 216-220°C percentage yield: 42.23%
Rf value: 0.72 (ethylacetate: acetone(9:1))
IR (KBr) 3284, 3154 (N-H str. Of 1º amine), 3081 (arom. –CH str), 
1493 (C=C str in aromatic hydrocarbons), 1256 (C-N str. Of amino grp), 
1141 (C-F str);1H NMR (DMSO, 400 MHz) δ6.697 (s, 1 H), δ6.694 (s, 
1H), δ6.676 (s, 1H);13C NMR (DMSO, 100MHz) δ163.44, 161.01, 160.29, 
159.02, 149.06, 149.00, 148.88, 130.68, 130.59, 129.91, 123.46; ESI 
MS (m/z relative abundance) 187 [(M+H)+], 178 [(C7H3F2N2S)+], 170 
[(C7H2F2S)+, 100].
Table 6: Drug-likeness assessments of the benzothiazole derivatives
Compound code Molecular weight Number of HBA Number of HBD C Log P Number of ROT.B n violation
DBT1 219.096 2 2 3.238 0 0
DBT2 186.186 2 2 2.209 0 0
DBT3 328.784 2 5 4.348 2 0
DBT4 309.35 0 5 4.316 3 0
Table 7: Results of ADMET ox parameters
Compound code BBB level Absorption level Solubility level Hepatotoxicity CYP2D6 inhibition PPB level
DBT1 1 0 3 1 1 1
DBT2 1 1 2 1 1 1
DBT3 1 1 3 1 1 1
DBT4 0 0 3 1 1 1
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DBT3
Molecular formula: C15H9ClN4OS molecular Weight: 328
Melting point: 192-196°C percentage yield: 16.20%
Rf value: 0.6 (chloroform: Methanol (9:1))
IR (KBr) 3476, 3367 (N-H str. Of 1º amine), 3029 (arom. –CH str), 1577 
(C=C str in aromatic hydrocarbons), 1266 (C-N str. Of amino grp), 1126 
(C-O-C str), 804 (C-Clstr).;1H NMR (DMSO, 400 MHz) δ6.58 (s, 1H), 
δ6.606 (d, J=1.2, 1H), δ6.697 (t, J=1.2, 2H), δ7.093 (t, J=8, 2H);13C NMR 
(DMSO, 100MHz) δ160, 167, 157, 158, 148.83,148.80, 133.10, 130.57, 
129.86, 127.08, 126.67, 126.17, 120.43, 112.94, 112.51, 102.23, 55.99, 
45.58, 40.11, 39.91, 39.70, 39.49, 39.28, 39.07; ESI MS (m/z relative 
abundance) 330 [(M+2)+,], 259 [(C14H8ClN2O)+], 243 [(C14H8ClN2)+, 100.
DBT4
Molecular formula: C16H11N3O2S molecular Weight: 309
Melting point: 190-194°C percentage yield: 18.20%
Rf value: 0.7 (ethylacetate: Acetone (9:1))
IR (KBr) 3072 (arom. –CH str),1457 (C=C str in aromatic hydrocarbons), 
1105 (C-O-C str), 2832 (C-O-CH3str);1H NMR (DMSO, 400 MHz) δ3.87 (s, 
1H), δ7.169 (s, 1H), δ7.625 (s, 1H), δ7.176 (d, J=1.2,1H), δ7.4 (t, J=8, 
2H);13C NMR (DMSO, 100MHz) δ160, 169, 157, 148.83, 148.80, 133, 
130.57, 129.86, 127.08, 126.67,125, 120.43, 112.94, 112.51, 102.23, 
55.49, 55.46, 45.58, 40.11, 39.91, 39.70, 39.49, 39.28, 39.07, 38.86; ESI 
MS (m/z relative abundance) 309 [(M)+,16], 277 [(C16H11N3O2)+, 27], 
225 [(C15H10N2)+, 100].
IR spectrum clearly suggested the formation of expected compounds.
H1 and C13 NMR were carried out using DMSO as solvent. C13 NMR 
signals H and13C NMR spectral data led to confirm the structure of 
targeted derivatives.
In vitro screening
In vitro cytotoxicity against MCF-7 cell lines by MTT assay
In vitro anticancer screening was carried out by MTT assay in breast 
cancer (MCF-7) cell lines. Four of the synthesized compounds were 
submitted to cytotoxicity study. Medium of cancer cell lines without 
samples were served as control. It is listed in Table 8.
Graphical representation of cytotoxic effect of prepared derivatives
The graph was plotted between concentration and percentage 
inhibition using Graph Pad Prism software.
All the compounds were screened for in vitro anticancer activity at different 
concentrations of 1000, 500, 250, 125, and 62.5 µg/mL. All the compounds 
possess good to moderate anticancer activity. Compounds DBT1, DBT2, 
and DBT3 were the most active compounds against MCF-7 cell lines with 
inhibitory concentration 50% of 70.0, 64.0, and 65.0, respectively.
CONCLUSION
All the derivatives show good docking scores when compared to 
standard drug and can be concluded that all designed ligands can be 
potent anticancer agents. The analysis of drug-likeness and toxicity 
studies strongly suggested the possibility of oral activity of the drug. 
As the concentration of compound being tested increased, the in-vitro 
anticancer activity also increased. Substitution on the 5th position of 
oxadiazole ring with aromatic group increases the activity. Introduction 
of an ethylene bridge between oxadiazole and aromatic substitution 
resulted in an analog with best binding potency. From the studied 
compounds, it was noticed that the presence of electron donating groups 
and electronegative halogens improve the activity of the compounds 
(DBT1, DBT2, DBT3, and DBT4). This revealed that the designed and 
the synthesized benzothiazole analogs had good anticancer activity.
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